IMMUNODOMINANT
Bringing science to life
IMMUNODOMINANT
Our mission is to use our AI-based small molecule platform to develop a pipeline of affordable, effective therapeutic drugs accessible to the entire market to help patients suffering from a variety of conditions, including long COVID.
Immunodominant is a drug discovery company specializing in progressing innovative research from academia into commercialized products.
Vitale with Lactoferrin
Immune support designed by an immunologist.
In addition to our drug discovery platform, we have designed a supplement by selectively choosing ingredients that promote health benefits based on multiple clinical studies and existing research. We bring a commitment to quality, substantiated research, and decades of expertise in immunology to formulate our nutritional supplements. And we want to empower you through education to help make the choices that are right for you.
20 IMMUNITY SUPPORT INGREDIENTS include ashwagandha, reishi, chaga, holy basil, turmeric, dandelion, echinacea, CoQ10, ginger root, elderberry, ceylon cinnamon, moringa, selenium, lactoferrin, Vitamin A, Vitamin B6, Vitamin B12, Vitamin D, and Vitamin C with zinc.*
The power of structure-based drug design.
Our platform and expertise in structure-based drug design enables us to identify compounds capable of modifying biological responses. This provides the foundation for an expanding pipeline with rapid development with IP covering novel therapies for prevention and treatment of autoimmune diseases and cancer.
Our AI-based small molecule platform accelerates drug discovery and enhances design efficiency
Small Molecule
An untapped opportunity for therapeutic intervention
World-class structural biology expertise develops novel antibodies, proteins and other biological molecules as drugs
AI-based Tech
Transforming drug discovery and computational design
Powerful supercomputer optimizes discovery and design through high throughput screening, modeling drug-protein interactions, and predicting reaction rates
Autoimmunity
Pursue a range of therapeutic targets linked by autoimmunity
- Infectious diseases
- Oncology
- Central nervous system
- Immunology
- Inflammation
Our founding member, Dr. David Ostrov, is an immunologist and structural biologist with decades of experience studying SARS coronaviruses. He uses structure-based drug design to discover and develop novel therapies for preventing and treating human diseases.
He is one of 32 international experts that serve on the Global Virus Network COVID Taskforce, where he is on the leading edge of research and global developments.
Immunodominant brings this unique insight when undertaking leading research in the prevention and treatment of SARS-COV-2. Our lead initiative is the clinical trails and commercialization of our therapeutic COVID drug with potent protection against variants, and long COVID.
For investment opportunities or to learn more, contact us below.